Effects of the thiazolidinediones on cardiovascular risk factors.
- 1 January 2002
- journal article
- research article
- Published by Springer Science and Business Media LLC in American Journal of Cardiovascular Drugs
- Vol. 2 (3), 149-156
- https://doi.org/10.2165/00129784-200202030-00002
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDLCell, 1998
- Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγCell, 1998
- Impaired Glucose Tolerance is Normalized by Treatment With the Thiazolidinedione TroglitazoneDiabetes Care, 1997
- Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.JCI Insight, 1995
- Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension.JCI Insight, 1994
- Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.JCI Insight, 1994
- Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groupsDiabetes Care, 1993
- Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM SubjectsDiabetes Care, 1992
- Book ReviewAmbulatory Pediatric CareThe New England Journal of Medicine, 1989